Kaeberlein Study on Rapamycin Therapy Published in eLife
August 26, 2016 in Research
The scientific journal eLife has published the latest results of a study led by Matt Kaeberlein, Professor of Pathology, and Piper Treuting, Associate Professor of Comparative Medicine and Chief of Comparative Pathology, on the long-term effects of short-term therapy on middle-aged mice treated with the drug rapamycin. The research showed that a transient dose of rapamycin, a drug approved by the FDA for certain organ transplant recipients, increased life expectancy and improved measures of healthy aging in the middle-aged mice.
A press release on the study can be found on UW Medicine’s online news site, HSNewsBeat.